Literature DB >> 28764234

Basic Concepts and Clinical Outcomes of Drug-Eluting Balloons for Treatment of Coronary Artery Disease: An Overview.

C D Ramakrishna1, Bhargav A Dave2, Pankaj S Kothavade3, Kajal J Joshi3, Ashok S Thakkar4.   

Abstract

The technology of percutaneous coronary intervention for atherosclerotic coronary artery disease has evolved considerably since its inception. Though Drug-Eluting Stent (DES) reduces the rate of restenosis, long-term safety outcomes and persistent restenosis in complex lesion subset remain area of concern. Recently, Drug-Eluting Balloon (DEB) represents a novel treatment strategy for atherosclerotic coronary artery disease. DEB demonstrated its added value in preclinical studies. Inspired by these results, several clinical trials particularly in complex lesion subsets have been started to explore the value of this novel treatment strategy in a broader range of lesions. This review would summarise material compositions and different characteristics and clinical outcomes of currently available DEB.

Entities:  

Keywords:  Balloon angioplasty; Balloon catheter; Drug-coated balloon; Percutaneous coronary intervention

Year:  2017        PMID： 28764234      PMCID： PMC5535426          DOI： 10.7860/JCDR/2017/26321.10000

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN： 0973-709X


  33 in total

1.  Recurrent coronary stent thrombosis.

Authors:  P Goethals; S Evrard; C Dubois
Journal:  Acta Cardiol       Date:  2000-12       Impact factor: 1.718

2.  The first patient to undergo coronary angioplasty--23-year follow-up.

Authors:  B Meier
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

3.  Drug-Coated Balloon Angioplasty for De Novo Stenosis: The Balloon is Back…Reloaded!

Authors:  Robert A Byrne; Michael Joner
Journal:  JACC Cardiovasc Interv       Date:  2015-11-25       Impact factor: 11.195

4.  Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.

Authors:  Francesco Liistro; Italo Porto; Paolo Angioli; Simone Grotti; Kenneth Ducci; Giovanni Falsini; Leonardo Bolognese
Journal:  Am Heart J       Date:  2013-10-07       Impact factor: 4.749

5.  A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial.

Authors:  Pieter R Stella; Anouar Belkacemi; Christophe Dubois; Hendrik Nathoe; Jo Dens; Christoph Naber; Tom Adriaenssens; Eric van Belle; Pieter Doevendans; Pierfrancesco Agostoni
Journal:  Catheter Cardiovasc Interv       Date:  2012-03-15       Impact factor: 2.692

Review 6.  IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.

Authors:  Susan Peterson; Melissa Hasenbank; Claudio Silvestro; Shashank Raina
Journal:  Adv Drug Deliv Rev       Date:  2016-10-19       Impact factor: 15.470

7.  Emergency stenting for acute occlusion after coronary balloon angioplasty.

Authors:  U Sigwart; P Urban; S Golf; U Kaufmann; C Imbert; A Fischer; L Kappenberger
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

8.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

Authors:  A R Grüntzig; A Senning; W E Siegenthaler
Journal:  N Engl J Med       Date:  1979-07-12       Impact factor: 91.245

Review 9.  Paclitaxel-eluting balloon: from bench to bed.

Authors:  Axel De Labriolle; Rajbabu Pakala; Laurent Bonello; Gilles Lemesle; Mickey Scheinowitz; Ron Waksman
Journal:  Catheter Cardiovasc Interv       Date:  2009-04-01       Impact factor: 2.692

Review 10.  Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis.

Authors:  Georg M Fröhlich; Alexandra J Lansky; Dennis T Ko; Olga Archangelidi; Rodney De Palma; Adam Timmis; Pascal Meier
Journal:  BMC Med       Date:  2013-05-08       Impact factor: 8.775
View more
  2 in total

1.  Hydrogen sulfide-releasing peptide hydrogel limits the development of intimal hyperplasia in human vein segments.

Authors:  Alban Longchamp; Kuljeet Kaur; Diane Macabrey; Celine Dubuis; Jean-Marc Corpataux; Sébastien Déglise; John B Matson; Florent Allagnat
Journal:  Acta Biomater       Date:  2019-07-26       Impact factor: 8.947

2.  In Vitro and In Vivo Comparative Evaluation of a Shellac-Ammonium Paclitaxel-Coated Balloon versus a Benchmark Device.

Authors:  Congying Xia; Yunhan Jiang; Shuangshuang Li; Dan Xiong; Xiaojie Chen; Yufang Chen
Journal:  J Interv Cardiol       Date:  2021-05-25       Impact factor: 2.279
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.